Aura Biosciences (NASDAQ:AURA) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

by · The Cerbat Gem

Aura Biosciences (NASDAQ:AURA – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.02, Zacks reports.

Aura Biosciences Stock Down 2.4 %

Shares of AURA traded down $0.26 during midday trading on Wednesday, reaching $10.39. The company had a trading volume of 42,103 shares, compared to its average volume of 175,165. The firm has a 50 day simple moving average of $9.69 and a 200-day simple moving average of $8.49. Aura Biosciences has a 1-year low of $6.63 and a 1-year high of $12.38.

Wall Street Analysts Forecast Growth

AURA has been the subject of a number of research analyst reports. Scotiabank raised their price target on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. JMP Securities upped their price objective on shares of Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a report on Friday, September 13th. HC Wainwright raised their price target on shares of Aura Biosciences from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Finally, Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, Aura Biosciences has a consensus rating of “Buy” and an average price target of $23.00.

Check Out Our Latest Analysis on AURA

Insiders Place Their Bets

In other news, CFO Julie B. Feder sold 25,131 shares of the company’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $12.03, for a total transaction of $302,325.93. Following the completion of the transaction, the chief financial officer now directly owns 134,276 shares of the company’s stock, valued at approximately $1,615,340.28. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Aura Biosciences news, CFO Julie B. Feder sold 25,131 shares of the company’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $12.03, for a total transaction of $302,325.93. Following the completion of the transaction, the chief financial officer now owns 134,276 shares in the company, valued at approximately $1,615,340.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO Mark Plavsic sold 7,383 shares of Aura Biosciences stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the sale, the chief technology officer now directly owns 121,132 shares in the company, valued at $1,193,150.20. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 67,259 shares of company stock worth $780,699 in the last quarter. 5.40% of the stock is owned by company insiders.

About Aura Biosciences

(Get Free Report)

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Recommended Stories